An increase in dementia numbers and global trends in population aging across the world
prompts the need for new medications to treat the complex biological dysfunctions, such as …

Alzheimer's disease (AD) is the leading cause of dementia worldwide. Even though the
number of AD patients is rapidly growing, there is no effective treatment for this …

Alzheimer's disease (AD) is a severe, chronic and progressive neurodegenerative disease
associated with memory and cognition impairment ultimately leading to death. It is the …

Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for
an increasing number of people and countries. Populations suffering from AD financially …

The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm “one‐drug …

Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly population
worldwide. Despite the major unmet clinical need, no new medications for the treatment of …

A major hurdle for the treatment of neurodegenerative disorders is the inability of drug
molecules to cross the blood-brain barrier (BBB). Many anti-Parkinson and anti-Alzheimer …

Lower generation PAMAM dendrimers have an immense potential for drug delivery with
lower toxicity, but these dendrimers yet need certain basic ameliorations. In this study, the …

Memantine (3, 5-dimethyladamantan-1-amine) is an orally active, noncompetitive N-methyl-
D-aspartate receptor (NMDAR) antagonist approved for treatment of moderate-to-severe …

Multitarget drug discovery is one of the hottest topics and most active fields in the search for
new molecules against Alzheimer's disease (AD). Over the last 20 years, many promising …